A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2004
11/04/2004	CA2526915A1 Methods of treating diseases responsive to induction of apoptosis and screening assays
11/04/2004	CA2526914A1 Compositions and methods relating to stop-1
11/04/2004	CA2526897A1 4-anilino-quinazoline derivatives as antiproliferative agents
11/04/2004	CA2526887A1 Splice variants of human voltage-gated calcium channel alpha2delta-2 subunit designated-alpha2delta2-a and alpha2delta2-b
11/04/2004	CA2526880A1 Cyclic quaternary amino derivatives as modulators of chemokine receptors
11/04/2004	CA2523364A1 Cannabinoid receptor ligands and uses thereof
11/04/2004	CA2523358A1 Method for identifying an anti-streptococcal agent and its use for treating streptococcal infections
11/04/2004	CA2523260A1 Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
11/04/2004	CA2523218A1 Oral pharmaceutical formulations of acid-labile active ingredients and process for making same
11/04/2004	CA2523157A1 Use of dipyridamole or mopidamole for treatment and prevention of thrombo-embolic diseases and disorders caused by excessive formation of thrombin and/or by elevated expression ofthrombin receptors
11/04/2004	CA2523077A1 Imidazopyridine compounds having 5-ht4 receptor agonistic activity and 5-ht3 receptor antagonistic activity
11/04/2004	CA2523042A1 Stabilized derivatives of ascorbic acid
11/04/2004	CA2522980A1 Water soluble wortmannin derivatives
11/04/2004	CA2522960A1 Therapeutic combination of a cox-2 inhibitor and an aromatase inhibitor
11/04/2004	CA2522946A1 Selective spirocyclic glucocorticoid receptor modulators
11/04/2004	CA2522828A1 Di-glycosil glyceryl compounds for the stabilisation and preservation of biomaterials
11/04/2004	CA2522810A1 4-(4-trans-hydroxycyclohexyl)amino-2-phenyl-7h-pyrrolo[2,3d]pyrimidine hydrogen mesylate and its polymorphic forms
11/04/2004	CA2522803A1 Substituted pyrimidinones and pyrimidinthiones as crf antagonists
11/04/2004	CA2522793A1 Novel substance having .alpha.-glucosidase inhibiting activity and food containing the same
11/04/2004	CA2522759A1 Substituted isochroman compounds for the treatment of metabolic disorders, cancer and other diseases
11/04/2004	CA2522751A1 Novel immunogenic compositions for the prevention and treatment of meningococcal disease
11/04/2004	CA2522737A1 Method for monitoring blood flow and metabolic uptake in tissue with radiolabeled alkanoic acid
11/04/2004	CA2522718A1 A novel method of modulating bone-related activity
11/04/2004	CA2522700A1 Methods of treating diseases responsive to induction of apoptosis and screening assays
11/04/2004	CA2522682A1 Indazole derivatives as jnk inhibitors
11/04/2004	CA2522667A1 Combination of a cox-2 inhibitor and an alkylating-type antineoplastic agent for treatment of neoplasia
11/04/2004	CA2522662A1 Compositions for delivery of drug combinations
11/04/2004	CA2522637A1 Modified irna agents
11/04/2004	CA2522580A1 A medicament for the two-step perioperative therapy of solid tumours
11/04/2004	CA2522562A1 2-phenyl-benzimidazol and 2-phenyl-imidazo-`4,5!-pyridine derivatives as checkpoint kinase cds1 (chk2) inhibitors for the treatment of cancer
11/04/2004	CA2522560A1 Antisense modulation of apolipoprotein c-iii expression
11/04/2004	CA2522536A1 Five-membered heterocyclic derivative
11/04/2004	CA2522497A1 Yeast ectopically expressing abnormally processed proteins and uses therefor
11/04/2004	CA2522354A1 8beta-vinyl-11beta-(alpha-substituted)alkyl-estra-1,3,5(10)-trienes
11/04/2004	CA2522351A1 Compositions and methods for treating body malodor and fungal overgrowth in mammals
11/04/2004	CA2522300A1 Treatment of angiotensin ii related disease
11/04/2004	CA2522184A1 Desmoglein 4 is a novel gene involved in hair growth
11/04/2004	CA2521625A1 Heterocyclic cyclopentyl tetrahydroisoquinoline and tetrahydropyridopyridine modulators of chemokine receptor activity
11/04/2004	CA2521538A1 Cannabinoid receptor ligands and uses thereof
11/04/2004	CA2521531A1 Pharmaceutical composition comprising edible acids or the acid salts and its use
11/04/2004	CA2521504A1 Method and kit for controlling bleeding
11/04/2004	CA2520908A1 Aryl compounds as modulators of ppars and methods of treating metabolic disorders
11/04/2004	CA2520886A1 Pharmaceutical compositions for hepatitis c viral protease inhibitors
11/04/2004	CA2520647A1 Compositions containing lactulose for treating rotavirus infections
11/04/2004	CA2520527A1 Compositions of cyclooxygenase-2 selective inhibitors and 5-ht1b/1d agonists for the treatment and prevention of migraine
11/04/2004	CA2520360A1 A method of providing a steroid-sparing benefit with a cyclooxygenase-2 inhibitor and compositions therewith
11/04/2004	CA2520197A1 Sachet for a pharmaceutical composition
11/04/2004	CA2519897A1 Modulation of telomere-initiated cell signaling
11/04/2004	CA2519772A1 Use of acetaminophen for providing a sustained therapeutic effect
11/04/2004	CA2519552A1 Extruded particles containing adverse agents such as opioid antagonists to decrease drug abuse potential
11/04/2004	CA2519338A1 Antineoplastic combinations
11/04/2004	CA2519164A1 Compositions comprising hyaluronic acid for the prevention of urogenital infections
11/04/2004	CA2518336A1 Polyethelene glycol link glp-1 compounds
11/04/2004	CA2517560A1 Thyronamine derivatives and analogs and methods of use thereof
11/04/2004	CA2517265A1 Trospium containing compositions
11/04/2004	CA2497410A1 Antibacterial pyrazole carboxylic acid hydrazides
11/03/2004	EP1473369A2 Compositions and methods for delivery of genetic material
11/03/2004	EP1473367A1 Means and methods for diagnosing and treating affective disorders
11/03/2004	EP1473365A1 Angiogenesis inhibitors
11/03/2004	EP1473308A1 Derivatives of starch for clinic use, especially parenteral
11/03/2004	EP1473303A1 Novel proteins and dnas thereof
11/03/2004	EP1473300A1 Pharmaceutical composition for the treatment of psoriasis and other skin diseases
11/03/2004	EP1473298A1 Supermolecular carboplatinum derivatives, their preparation and pharmaceutical composition containing them as active ingredient and applications of the compositions
11/03/2004	EP1473295A1 Fused bicyclic pyrimidine derivatives
11/03/2004	EP1473294A2 Substituted 1,3-oxathiolanes with antiviral properties
11/03/2004	EP1473289A1 Preventives or remedies for alzheimer's disease or amyloid protein fibrosis inhibitors containing nitrogen-containing heteroaryl compounds
11/03/2004	EP1473288A1 Nitric ester derivatives of COX-2 inhibitors and their use for treating inflammation and cardiovascular diseases
11/03/2004	EP1473043A1 Pharmaceutical combination for the treatment of diseases involving cell proliferation, migration or apotosis of myeloma cells, or angiogenesis
11/03/2004	EP1473041A2 Anti-allergic pharmaceutical composition
11/03/2004	EP1473040A1 Use of human parathyroid hormone
11/03/2004	EP1473039A1 Use of inhibitors and antisense oligonucleotides of BTK for the treatment of proliferative mastocytosis
11/03/2004	EP1473037A1 Treatment of hPMV infections with Ribavirin
11/03/2004	EP1473036A1 Zolpidem hemitartrate solvate
11/03/2004	EP1473035A1 Leflunomide of high purity
11/03/2004	EP1473034A1 Use of an inhibitor of the phosphodiesterase-4-enzyme (PDE4) alone or in combination with relaxin and derivatives thereof for the manufacture of a medicament to promote decidualization of endometrial cells and to increase fertility
11/03/2004	EP1473033A1 Medicinal composition containing 2,2-dichloro-12-(4-chlorophenyl)dodecanoic acid
11/03/2004	EP1473032A1 Use of taurine, homotaurine and/or methionine for inducing analgesia or anesthesia
11/03/2004	EP1473031A1 Sucrose ester - C20 to C28 alcohol formulations
11/03/2004	EP1473030A1 Extended release Venlafaxine tablet formulation
11/03/2004	EP1473003A2 Drug delivery device
11/03/2004	EP1472544A2 Diagnostics and therapeutics for diseases associated with a new human 5-ht6 receptor
11/03/2004	EP1472540A2 Methods and compositions in treating pain and painful disorders using 1465,1587, 2146, 2207, 32838, 336 and 52908
11/03/2004	EP1472536A2 Broad spectrum inhibitors
11/03/2004	EP1472515A2 MINRs AS MODIFIERS FO INSULIN RECEPTOR SIGNALING AND METHODS OF USE
11/03/2004	EP1472377A2 Genetic polymorphisms in the preprotachykinin gene
11/03/2004	EP1472376A2 Methods and compositions for treating urological disorders using 1435, 559, 34021, 44099, 25278, 641, 260, 55089, 21407, 42032, 46656, 62553, 302, 323, 12303, 985, 13237, 13601, 18926, 318, 2058 or 6351 mo
11/03/2004	EP1472375A1 Gene products differentially expressed in cancerous breast cells and their methods of use
11/03/2004	EP1472357A2 Elongase gene and method for producing polyunsaturated fatty acids
11/03/2004	EP1472351A2 Amino acid sequences capable of facilitating penetration across a biological barrier
11/03/2004	EP1472290A2 Cyclodextrin grafted biocompatible amphiphilic polymer and methods of preparation and use thereof
11/03/2004	EP1472287A1 Rhamnose binding protein
11/03/2004	EP1472278A2 Macrocyclic peptides active against the hepatitis c virus
11/03/2004	EP1472277A1 Fap-activated anti-tumor compounds
11/03/2004	EP1472272A1 Crystalline complexes of fluticasone 2-furoate
11/03/2004	EP1472270A1 Fractionation of phytosterol esters in oil
11/03/2004	EP1472269A1 RNA INTERFERENCE MEDIATED INHIBITION OF INTERLEUKIN GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
11/03/2004	EP1472267A2 Rna interference mediated inhibition of protein tyrosine phosphatase type iva (prl3) gene expression using short interfering nucleic acid (sina)
11/03/2004	EP1472261A2 The synthesis of naturally occuring ecteinascidins and related compounds
11/03/2004	EP1472260A2 Thieno(3,2-b)pyridones as antiviral compounds
11/03/2004	EP1472257A1 Inhibitors of alpha l beta 2 integrin mediated cell adhesion

1 ... 4904 4905 4906 4907 4908 4909 4910 4911 4912 4913 4914 4915 4916 4917 4918 4919 4920 4921 4922 4923 4924 ... 7860